Five-Year Persistence of Vedolizumab in Crohn's Disease: Results from a Real-World Cohort.

In contrast, in our cohort, although the difference did not reach statistical significance, we observed a trend toward better treatment persistence in patients previously exposed to biologics compared with biologic-naïve patients (56.5% vs. 33.3%, p = 0.139), a finding that might be related to the relatively small sample size.

also in 111,027 other papers